6CM
ARIA

683 Capital Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

683 Capital Management’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-100,000
Closed -$540K – 71
2014
Q3 		$540K Hold
100,000
– – 0.18% 51
2014
Q2 		$637K Hold
100,000
– – 0.24% 48
2014
Q1 		$806K Hold
100,000
– – 0.31% 46
2013
Q4 		$682K Buy
+100,000
New +$540K 0.19% 54

Other funds holding ARIA

SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

683 Capital Management's ARIA Position: Q4 2014 in Review

683 Capital Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q4 2014, closing a stake of 100,000 shares — an estimated $540K sold.

683 Capital Management first reported a position in ARIA in Q4 2013 and held it in 4 quarters. The position peaked at $806K in Q1 2014. 179 funds tracked by Wall St. Rank hold ARIA as of Q4 2014.

  • 683 Capital Management reported no remaining Ariad Pharmaceuticals Inc position as of Q4 2014 after selling out during the quarter.
  • 683 Capital Management sold 100,000 Ariad Pharmaceuticals Inc shares in Q4 2014, an estimated $540K.
  • 683 Capital Management first reported a position in Ariad Pharmaceuticals Inc in Q4 2013 and held it in 4 quarters.
  • 683 Capital Management's Ariad Pharmaceuticals Inc position peaked at $806K in Q1 2014.
  • 179 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q4 2014.

Based on 683 Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.